NeuroPace (NPCE) Q1 2025: RNS-Driven 24% Revenue Growth Anchors Margin Expansion and Portfolio Pivot
NeuroPace’s Q1 marked a decisive pivot to its RNS platform, with 24% revenue growth and a 77% gross margin, underpinned by operational leverage and clinical validation of its core therapy. The exit from SEEG distribution and focused investment in RNS clinical and software innovation signal a business model shift toward higher-margin, scalable neuromodulation. Management’s raised outlook and strategic clarity position NPCE for sustained growth, but execution on indication expansion and commercial scale will be key watchpoints for investors.
Summary
- Portfolio Refocus: SEEG exit and RNS prioritization sharpen NeuroPace’s margin and growth profile.
- Operational Leverage: RNS manufacturing scale and price discipline drove significant gross margin expansion.
- Growth Engine: Project CARE and new clinical data unlock broader adoption and set up future indication wins.
Performance Analysis
NeuroPace delivered 24% year-over-year revenue growth in Q1 2025, driven almost entirely by the RNS system, its brain-responsive neurostimulation therapy for drug-resistant epilepsy. RNS sales rose 26% (29% excluding Nautilus study implants from the prior year), reflecting both higher implant volumes and a record number of prescribers. The SEEG (stereo-EEG) diagnostic business contributed modestly, but its lower margin profile diluted overall profitability.
Gross margin climbed to 77%, up from 73.6% in Q1 2024, as higher RNS production volumes absorbed fixed costs and recent price increases took hold. Operating expenses rose 8%, but revenue growth outpaced cost expansion, yielding improved operating leverage. Net loss narrowed to $6.6 million from $8.9 million a year ago, while cash burn was $7.5 million, with a bolstered $66.3 million cash position following a $75 million equity raise. Management raised full-year revenue guidance and maintained a 73% to 75% gross margin outlook, signaling confidence in RNS momentum and cost discipline.
- Margin Expansion: RNS scale and pricing drove a 340 basis point gross margin gain, with SEEG drag set to fade post-exit.
- Operating Leverage: Expense growth trailed revenue, demonstrating cost discipline amid commercial investments.
- Cash Position: Balance sheet strength supports runway through break-even, reducing near-term financing risk.
The quarter’s performance validates the RNS-centric model, but future growth will depend on successful execution of indication expansion, Project CARE adoption, and next-gen product launches.
Executive Commentary
"We believe that the best use of our resources to create value for the NeuroPace community of patients, clinicians, and shareholders is by doing what we are uniquely positioned to do, which is to focus on the significant opportunities within our RNS portfolio and make the RNS system the standard of care for the treatment of drug-resistant epilepsy patients."
Joel Becker, Chief Executive Officer
"Gross margin for our R&S products was particularly strong this quarter benefiting from improved manufacturing efficiency as fixed overhead costs were absorbed across a higher volume of units. This growth was partially offset by the lower gross margin from distribution of SEEG products."
Rebecca Kuhn, Chief Financial Officer
Strategic Positioning
1. RNS System as Core Growth Platform
NeuroPace is doubling down on its RNS system, a closed-loop neurostimulation therapy for drug-resistant epilepsy, as the primary engine for revenue and margin expansion. The system’s clinical efficacy was underscored by new post-approval data showing an 82% median reduction in seizures at three years, and over 40% of patients achieving six months or more of seizure freedom. These outcomes position RNS as a superior alternative to VNS (vagus nerve stimulation) and DBS (deep brain stimulation), differentiating the product in a competitive neuromodulation landscape.
2. Project CARE and Commercial Scale
Project CARE, NeuroPace’s initiative to expand access to RNS by enabling community and Level 3/4 epilepsy centers, is driving both referral and implant growth. The company highlighted increasing referral volumes and new prescriber adoption, supported by targeted commercial investments and direct-to-patient marketing. The ability to train and support new centers, while maintaining high standards of procedural execution, is central to scaling adoption beyond academic hubs.
3. Portfolio Rationalization and Margin Focus
The decision to exit SEEG distribution reflects a strategic shift toward higher-margin, differentiated offerings. SEEG, a diagnostic tool for epilepsy surgery planning, historically delivered around 50% gross margin—well below RNS’s 78%+. By winding down SEEG sales through early 2026, NeuroPace will further enhance its blended margin profile and free up resources for RNS clinical, commercial, and product development priorities. The exit is not expected to materially impact 2025 revenue, as transition inventory sales are included in guidance.
4. Indication Expansion and Pipeline Execution
Clinical development is a major growth lever, with active programs in idiopathic generalized epilepsy (Nautilus study) and pediatric focal epilepsy. The company expects to submit pivotal data for Nautilus and the pediatric indication to the FDA in the second half of 2025, leveraging real-world evidence and partnerships with organizations like NEST and PERC. Successful label expansion would open new patient populations and further entrench RNS as a standard of care.
5. Next-Generation Product and Software Innovation
NeuroPace is investing in AI-powered software and next-gen device platforms, with a major software release for the RNS320 planned for late 2025. While monetization options (e.g., subscription, data services) are under consideration, near-term focus remains on driving ease of use, efficiency, and implant growth within the current business model.
Key Considerations
This quarter marks an inflection point as NeuroPace pivots to a pure-play RNS business, with operational improvements and clinical momentum setting the stage for multi-year growth.
Key Considerations:
- Margin Tailwind from SEEG Exit: Phasing out SEEG will structurally lift gross margins and reduce operational complexity.
- Clinical Data as Commercial Catalyst: New RNS outcomes data is energizing prescriber engagement and differentiating the product in a crowded field.
- Commercial Execution Risk: Scaling Project CARE and direct-to-patient outreach requires continued investment and disciplined field support.
- Pipeline and Indication Expansion: Timely FDA submissions and positive readouts are critical for sustaining growth beyond core focal epilepsy.
- Balance Sheet Resilience: The $66 million cash balance and reduced cash burn lower dilution risk and support strategic flexibility through break-even.
Risks
Execution on commercial scale, especially in community settings, remains a key risk as the company transitions from academic to broader market penetration. Delays or negative outcomes in indication expansion studies (Nautilus, pediatric) could slow the growth trajectory. Margin variability may persist quarter to quarter due to product mix and the SEEG wind-down. Competition from established neuromodulation players and evolving reimbursement frameworks present ongoing external risks.
Forward Outlook
For Q2 and the remainder of 2025, NeuroPace guided to:
- Full-year revenue of $93 million to $97 million (16% to 21% growth over 2024)
- Gross margin of 73% to 75%, with some quarterly variability expected
- Operating expenses of $92 million to $95 million, including $11 million in stock-based compensation
Management emphasized:
- RNS system sales will remain the primary growth driver, with SEEG contributions tapering off
- Minimal impact from new US tariffs on cost structure and gross margins
- Continued focus on operating discipline to drive toward cash flow break-even by year-end 2027
Takeaways
NeuroPace’s Q1 results validate its strategic pivot to a focused, high-margin RNS business, supported by clinical data, commercial execution, and a strengthened balance sheet.
- RNS Outperformance: The core therapy’s adoption and clinical validation are expanding the addressable market and driving profitable growth.
- Portfolio Streamlining: The SEEG exit will structurally improve margins and sharpen operational focus, but requires careful customer transition management.
- Growth Hinges on Execution: Investors should monitor progress on indication expansion, Project CARE scaling, and next-gen product launches as key catalysts for sustained outperformance.
Conclusion
NeuroPace’s Q1 2025 marked a strategic and operational inflection, as the company leverages its RNS platform, clinical leadership, and focused execution to drive growth and margin expansion. Sustained success will depend on delivering pipeline milestones and scaling commercial infrastructure in a competitive neuromodulation market.
Industry Read-Through
NeuroPace’s RNS-centric strategy and strong clinical data highlight a broader shift in neuromodulation toward evidence-based, high-margin therapeutic platforms. The exit from lower-margin, commoditized diagnostics like SEEG foreshadows similar portfolio rationalizations across the sector as companies prioritize differentiated, scalable solutions. The emphasis on direct-to-patient engagement and community center adoption signals increasing decentralization of advanced therapies, a trend likely to reshape commercial models for device makers. Successful label expansion and digital innovation will be key differentiators as reimbursement and competitive intensity rise in neurotechnology.